Clinical Trial Update: Role of CYP2B6, CYP3A4, and MDR1 in the Metabolic Clearance of Methadone [Phase 1]

View source ↗

Summary

Phase 1 trial examining how CYP2B6, CYP3A4, and MDR1 influence the metabolic clearance of methadone.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Substance Use Disorder

Drugs mentioned

• Methadone (methadone)

Snippet

Sponsor: University of Washington | Conditions: Substance-Related Disorders | Phase 1 | Status: UNKNOWN